Avenue Therapeutics Inc (ATXI)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Alexandra MacLean
Employees:
4
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY 10014
781-652-4500

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain.

Data derived from most recent annual or quarterly report
Market Cap 1.26 Million Shares Outstanding8.183 Million Avg 30-day Volume 5.336 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.45
Price to Revenue0.0 Debt to Equity0.0 EBITDA-9.54 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value4.764 Million
Current Ratio0.038 EPS Growth0.625 Quick Ratio0.035
1 Yr BETA 0.6881 52-week High/Low 2.35 / 0.14 Profit Margin0.0
Operating Cash Flow Growth-143.9741 Free Cash Flow to Firm (FCFF) TTM -7.269 Million Free Cash Flow to Equity (FCFE) TTM-11.432 Million
Altman Z-Score-328.9403
View SEC Filings from ATXI instead.

View recent insider trading info

Avenue Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ATXI (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ATXI

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-11-28 by DAVIDOW ROBERT L
  • 4: filed on 2023-07-05 by JIN DAVID
  • 4: filed on 2023-07-05 by KRANZLER JAY D
  • 4: filed on 2023-07-05 by OLTMANS CURTIS GALE
  • 4: filed on 2023-07-05 by HERSKOWITZ NEIL
  • 4: filed on 2023-07-03 by MACLEAN ALEXANDRA
  • 4: filed on 2023-04-04 by FORTRESS BIOTECH, INC.
  • 4: filed on 2023-01-04 by FORTRESS BIOTECH, INC.
  • 4: filed on 2022-10-13 by INVAGEN PHARMACEUTICALS, INC.
  • 3: filed on 2022-08-03 by MACLEAN ALEXANDRA

    • Events (8k)

  • 8-K: filed on 2023-11-24:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-11-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-11-02:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-28:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-09-27:
    Item 8.01: Other Events
  • 8-K: filed on 2023-09-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-21:
    Item 8.01: Other Events
  • 8-K: filed on 2023-07-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-26:
    Item 5.07: Submission of Matters to a Vote of Security Holders

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    DAVIDOW ROBERT L

    • 10% Owner
    		 1,926,800 2023-10-31 1

    ROSENWALD LINDSAY A MD

    • Director
    		 354,318 2023-09-08 2

    FORTRESS BIOTECH, INC.

    • 10% Owner
    		 1,032,390 2023-09-08 3

    KRANZLER JAY D

    • Director
    		 0 2023-06-30 1

    HERSKOWITZ NEIL

    • Director
    		 0 2023-06-30 1

    OLTMANS CURTIS GALE

    • Director
    		 0 2023-06-30 1

    CHARLES FAITH L.

    • Director
    		 0 2023-06-30 1

    JIN DAVID INTERIM PFO AND COO

    • Officer
    		 0 2023-06-30 1

    MACLEAN ALEXANDRA CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-06-29 1

    INVAGEN PHARMACEUTICALS, INC.

    • 10% Owner
    		 0 2022-10-11 0

    LU LUCY PRESIDENT, CEO

    • Officer
    • Director
    		 748,949 2021-12-17 0

    VAZZANO JOSEPH WALTER CHIEF FINANCIAL OFFICER

    • Officer
    		 165,757 2021-12-17 0

    INGRAM ELIZABETH GARRETT

    • Director
    		 16,000 2019-09-12 0

    MOORE THOMAS GREGORY

    • Director
    		 0 2019-04-30 0

    SAXENA NISHANT

    • Director
    		 0 2019-02-08 0

    GOGTAY JAIDEEP ASHOK

    • Director
    		 0 2019-02-08 0

    PALEY JEFFREY

    • Director
    		 79,663 2018-12-03 0

    WEISS MICHAEL S

    • Director
    		 24,663 2018-08-07 0

    SAMAD AKHTAR

    • Director
    		 64,663 2018-08-07 0

    REINES SCOTT INTERIM CHIEF MEDICAL OFFICER

    • Officer
    		 45,000 2018-08-07 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 22:15:04 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 21:45:04 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 21:15:04 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 20:45:04 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 20:15:07 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 19:45:04 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 19:15:03 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 18:45:03 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 18:15:04 UTC -103.2926 108.6126 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 17:45:03 UTC -106.16 111.48 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 17:15:03 UTC -106.16 111.48 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 16:45:05 UTC -106.16 111.48 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 16:15:04 UTC -106.16 111.48 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 15:45:04 UTC -106.16 111.48 700000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 15:15:04 UTC -106.16 111.48 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 14:45:04 UTC -109.7664 115.0864 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 14:15:03 UTC -109.7664 115.0864 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 13:45:03 UTC -118.4017 123.7217 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 13:15:04 UTC -118.4017 123.7217 750000
    AVENUE THERAPEUTICS INC ATXI 2023-12-08 12:45:05 UTC -118.4017 123.7217 500000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments